Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 103 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Juvenile Idiopathic Arthritis (JIA) Clear all
Completed Phase 2 Interventional

Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis

NCT00000429
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Calcium carbonate
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 10, 2026, 2:38 PM EDT
Terminated No phase listed Observational Results available

Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis

NCT00688545
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, nsNSAIDs
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 10, 2026, 2:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions

NCT03510442
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
1 Day to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Terminated Not applicable Interventional Results available

Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis

NCT00868751
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
Interventions
tocilizumab
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
2 Years to 16 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis

NCT00001614
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid, Uveitis
Interventions
Chicken type II collagen
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT01803321
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
rilonacept (IL-1 Trap), Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
4 Years to 20 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Los Angeles, California • Wilmington, Delaware • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 10, 2026, 2:38 PM EDT
Not listed Not applicable Interventional

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Results available

Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

NCT01563185
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
800 mg ibuprofen/26.6 mg famotidine
Drug
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
New Orleans, Louisiana • Boston, Massachusetts • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 10, 2026, 2:38 PM EDT
Not listed Phase 3 Interventional

The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis

NCT00012506
View directory record Official record
Conditions
Uveitis, Arthritis, Juvenile Rheumatoid
Interventions
TNFR:Fc
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Results available

Adalimumab in JIA-associated Uveitis Stopping Trial

NCT03816397
View directory record Official record
Conditions
Uveitis, JIA
Interventions
Adalimumab, Placebo
Biological · Other
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 10, 2026, 2:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

NCT07065747
View directory record Official record
Conditions
Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT00889863
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions
canakinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 10, 2026, 2:38 PM EDT
Terminated Phase 3 Interventional Results available

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

NCT00886769
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 10, 2026, 2:38 PM EDT
Not yet recruiting Phase 4 Interventional

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

NCT07699107
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Interventions
Adalimumab/Biosimilar
Biological
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy

NCT02277444
View directory record Official record
Conditions
Arthritis, Juvenile
Interventions
Golimumab, Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
14
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 10, 2026, 2:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Juvenile Rheumatoid Arthritis Research Registry

NCT00090571
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 10, 2026, 2:38 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

NCT02418273
View directory record Official record
Conditions
Osteoporosis, Juvenile Rheumatoid Arthritis, Dermatomyositis, Polyarthritis, Systemic Lupus Erythematosis, Vasculitis, Glucocorticoid-induced Osteoporosis
Interventions
denosumab
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

NCT00048542
View directory record Official record
Conditions
Arthritis, Juvenile Idiopathic
Interventions
Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
4 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Results available

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

NCT01734382
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Not applicable Interventional Results available

Sleep Shared-Management Intervention for Children With Juvenile Idiopathic Arthritis

NCT04066205
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
SLEEPSAMRT
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
8 Years to 13 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis

NCT00001862
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis, Uveitis
Interventions
Enbrel
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Not applicable Interventional Results available

Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA

NCT00289094
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Juvenile Rheumatoid Arthritis, Avascular Necrosis of Bone
Interventions
Total knee replacement
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
Billings, Montana • Vancouver, Washington
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 10, 2026, 2:38 PM EDT
No Longer Available No phase listed Expanded access

Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab

NCT00862758
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
11 Years to 12 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Results available

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

NCT01544114
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
VIMOVO 250/20, VIMOVO 375/20, VIMOVO 500/20
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 16 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
17
States / cities
Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 10, 2026, 2:38 PM EDT